Company intelligence / Profile preview

Arthritis Innovation Corporation

Toronto, Ontario, Canadaaic.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 3

Overview

AIC's lead product F14 is in Phase 3 clinical trials. F14 is a sustained-release formulation of celecoxib (Celebrex) administered intra-articularly after total knee replacement surgery. The company completed patient enrollment in the first of two Phase 3 clinical studies. A previous Phase 2 study was completed (NCT03541655).

Therapeutic areas: OtherRheumatology
Modalities: Small molecules (NSAIDs, specifically celecoxib)
Industry: Biotech

Drug pipeline

1 asset

F14

Partnerships

MedinCell (technology partner)

Beyond the preview

Go deeper on Arthritis Innovation Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arthritis Innovation Corporation.

Explore the full profile